Clinical study of double filtration plasmapheresis for treatment of refractory myasthenia gravis.
- Author:
Jiang-tao HUO
1
;
Hai-li LONG
;
Xiang LUO
;
Jin-zhi XU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Autoantibodies; blood; Child; Female; Filtration; Humans; Male; Middle Aged; Myasthenia Gravis; blood; therapy; Plasma Exchange; methods; Receptors, Cholinergic; immunology; Retrospective Studies; Treatment Outcome
- From: Journal of Southern Medical University 2007;27(3):355-357
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo assess the therapeutic effect, timing of administration, complication prevention and management of the double filtration plasmapheresis (DFP) in the treatment of refractory myasthenia gravis (MG).
METHODSThirty-one patients with refractory MG were treated with KM 8800 membrane plasmapheresis monitor. DFP was performed every 3 days and the exchanging liquid was composed of 50 ml of 20% albumen and 1000 ml plasma substitute. Physical examination for absolute clinical score and blood sample was collected for AchR-Ab determination early in the morning on days 0, 3, 7, 14 of DFP.
RESULTSWith a total effective rate of 91.9%, complete recovery, basic recovery, improvement, and response was achieved in 2, 4, 11, and 17 patients, respectively, whereas the other 3 failed to respond. Hypotension occurred twice in 2 cases and was corrected after symptomatic treatment.
CONCLUSIONDFP may effectively lower blood AchR-Ab level of with minimal complications, and can be valuable for treatment of refractory MG.
